Comparative efficacy and safety between ablative therapies or surgery for small hepatocellular carcinoma: a network meta-analysis
Gui-Qi Zhu, Min Sun, Wei-Ting Liao, Wei-Hua Yu, Shao-Lai Zhou, Zheng-Jun Zhou, show all
Received 10 Dec 2017, Accepted 19 Jul 2018, Accepted author version posted online: 20 Jul 2018, Published online: 25 Jul 2018
Background: Major treatments for small hepatocellular carcinoma (SHCC) include percutaneous ethanol injection (PEI), percutaneous acetic acid injection (PAI), radiofrequency ablation (RFA), or surgical resection (SR). We aimed to compare these therapies concerning with effectiveness and safety.
Methods: Cochrane Library, PubMed, and Embase were searched for randomized controlled studies (RCTs) from inception to 30 April 2017. Odds ratios (OR) for proportion dead (PD), local recurrence (LR) and adverse events (AEs).
Results: Fourteen RCTs were identified. Compared with SR, PEI (OR 2.79, CrI 1.25, 6.45, p < 0.01) provided a significantly increased risk of PD. Similarly, PEI (OR 4.29, CrI 1.18, 18.35, p < 0.01) yielded more LR than SR. Also, SR significantly conferred more AEs than RFA (OR 0.10; CrI 0.02, 0.35, p < 0.01), PEI (OR 0.06; CrI 0.01, 0.31, p < 0.01). Besides, RFA conferred the highest efficacy for survival, time to recurrence, and new development of HCC.
Conclusions: SR was superior to PEI. Although SR achieved highest cumulative ranking probabilities in clinical efficacy, it obtained a low benefit-to-risk ratio for patients. RFA was superior to the other ablative therapies. For tumor sizes > 2 cm or ≤ 2 cm in diameter, SR conferred non-significant effects compared with other therapies for SHCC.
KEYWORDS: Small hepatocellular carcinoma, network meta-analysis, randomized controlled trials, ablative therapy, liver resection
Additional information
Funding
This work was supported by the National Natural Science Fund of China [Grant numbers: No. 81672330; No. 81472218].作者: StephenW 时间: 2018-7-27 17:59